Pharma Nordic has expanded its distribution agreement with Altamira Medica for Bentrio nasal spray, adding Sweden and Denmark, the companies announced. Bentrio is an OTC bentonite-based nasal spray gel marketed for the prevention and treatment of allergic rhinitis. In July 2023, Pharma Nordic acquired the distribution rights for Bentrio in Norway, and the company launched the product there earlier this year.
Altamira Medica Chairman and CEO Thomas Meyer commented, “We have been very pleased and impressed by Pharma Nordic’s market launch activities and success in Norway. It is therefore of mutual interest to expand in a next step the geographical scope of our collaboration to include Sweden and Denmark. We look forward to bringing Bentrio to patients in these two other countries and to continuing to build the product together with Pharma Nordic into one of the leading brands for allergic rhinitis management in Scandinavia.”
Pharma Nordic CEO Bent Andreassen said, “We received very favorable responses to Bentrio from members of the medical community and allergic rhinitis sufferers in Norway, showing a clear need for effective and safe treatment alternatives. With its drug-free and preservative-free formulation, as well as strong data on efficacy and tolerability, Bentrio is uniquely positioned to address patients’ unmet needs. We are very excited to continue the roll-out in Norway and to take Bentrio into the Swedish and Danish markets, which share many things in common, notably a passion for innovative health care products.”
Read the Altamira Therapeutics press release.
